NCT04946838

Brief Summary

Transcutaneous electrical nerve stimulation (TENS) is a non-invasive electro-physical modality used for several pain conditions including labor pain control. Despite several years of research, there is still no agreement within the literature regarding the selection of TENS parameters. It is aimed to investigate TENS1 alternating between 4 to 100 Hz compared to sham-TENS. The present study aims to evaluate TENS in combination with cardiotocography (CTG). The combination of TENS with CTG in a feedback-loop has not been reported in any studies before.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 23, 2021

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 1, 2021

Completed
8 days until next milestone

Study Start

First participant enrolled

July 9, 2021

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 13, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 13, 2021

Completed
Last Updated

August 30, 2021

Status Verified

August 1, 2021

Enrollment Period

1 month

First QC Date

June 23, 2021

Last Update Submit

August 27, 2021

Conditions

Keywords

TENSLabor painChildbirthRCTPilot study

Outcome Measures

Primary Outcomes (2)

  • Visual Analog scale (VAS)

    10-cm pain intensity scale with 0 cm is no pain and 10 cm is unbearable pain. Decreased cm after baseline measurement indicates pain relief.

    Baseline, 10 minutes post stimulation, 30 minutes post stimulation

  • Pain pressure threshold (PPT)

    Pain sensitivity measurement also defined as the minimum pressure needed to evoke a pain response measured in kPa. Increased kPa after baseline measurement indicates pain relief.

    Baseline, 10 minutes post stimulation, 30 minutes post stimulation

Secondary Outcomes (4)

  • Satisfaction of TENS

    Right after last measurements of VAS & PPT

  • Experienced pain reduction

    Right after last measurements of VAS & PPT

  • Interest in the use of TENS again

    Right after last measurements of VAS & PPT

  • Recommend TENS to others

    Right after last measurements of VAS & PPT

Study Arms (2)

TENS

EXPERIMENTAL

TENS with 4/100 Hz in frequency, 200 µs in pulse duration, and intensity individually adjusted.

Device: DS5 electrical stimulator

Sham-TENS

SHAM COMPARATOR

Sham with 100 Hz in frequency, 200 µs in pulse duration, and intensity below 5 mA.

Device: DS5 electrical stimulator

Interventions

TENS

Sham-TENSTENS

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Singleton pregnancy
  • Vertex presentation
  • Speak, read and understand Danish

You may not qualify if:

  • Gestational age \< 37+0 weeks
  • Gestational age \> to 41+6 weeks
  • High-risk pregnancies (including risk factors: eclampsia, pre-eclampsia, diabetes, gestational diabetes, hypertension (above 140/90), and hypotension (below 90/60), Intrauterine growth restriction (IUGR), polyhydramnious, and oligohydramnious).
  • Pre-gestational body mass index (BMI) above 40 kg/m2
  • Use of fetal scalp-electrode during the experiment
  • Use of pacemakers and other electronic implants
  • Severe arrhythmia
  • Present musculoskeletal illnesses (including myopathy and arthritis).
  • Chronic pain within last 6 months (Pelvic girdle pain (PGP) to a mild degree (VAS 0-6 cm) is accepted in the experiment. Severe degree (VAS 6-10 cm) (e.g. bedridden or difficulty walking) especially within 24 hours before birth is excluded).
  • Present/previous neurologic illnesses (including epilepsy, migraine, and sclerosis).
  • Present medicated mental disorders (including dementia, personality disorders, bipolar, ADHD, and anxiety).
  • Dermatological disorders (including skin allergy, tattoos or scars on the locations of electrodes)
  • Use of other long-acting pain relief before the experiment (including Epidural, Morphine less than 16 hours before experiment), Acupuncture, Paracetamol (less than 8 hours before experiment), Cocktail (less than 8 hours before experiment), nitrous oxide (less than one hour before experiment), sterile water injection (less than two hours before experiment).
  • Use of TENS 48 hours before the trial
  • Drug addiction defined as the use of cannabis, opioids or other drugs.
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Region Hospital Gødstrup

Herning, 7400, Denmark

Location

MeSH Terms

Conditions

Labor Pain

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Parisa Gazerani, PhD

    Aalborg University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
Double-blinded
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: 2 groups (TENS and sham)
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principle Investigator

Study Record Dates

First Submitted

June 23, 2021

First Posted

July 1, 2021

Study Start

July 9, 2021

Primary Completion

August 13, 2021

Study Completion

August 13, 2021

Last Updated

August 30, 2021

Record last verified: 2021-08

Data Sharing

IPD Sharing
Will share

Study protocol and individual participant data will be available.

Shared Documents
STUDY PROTOCOL
Time Frame
The study protocol will also be published after the manuscript publication. Expected to be published after September 2021.

Locations